Dyslipidemia and cardiovascular risk: the importance of early prevention

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study

(2008) Syed M. Mohiuddin et al.   AMERICAN HEART JOURNAL

Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non–HDL Cholesterol (from the SEACOAST I Study)

(2008) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia

(2008) Kevin C. Maki et al.   AMERICAN JOURNAL OF CARDIOLOGY

Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia

(2008) Richard H Karas et al.   American Journal of Cardiovascular Drugs

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

(2008) J. D. Brunzell et al.   DIABETES CARE

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2008) R. Scott et al.   DIABETES CARE

ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans

(2008) Tong Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia

(2008) John R. Guyton et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

(2008) Michael Miller et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis

(2008)   LANCET

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

(2008) GISSI-HF investigators   LANCET

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.

(2007) John F. Paolini et al.   AMERICAN JOURNAL OF CARDIOLOGY